NEXCELLA-Inverted-Color-2000x1500_nosubtitle_gray - rectangle.png
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
July 25, 2024 21:36 ET | Nexcella, Inc.
LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and...
NEXCELLA-Inverted-Color-2000x1500_nosubtitle_gray - rectangle.png
Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States
April 18, 2024 09:37 ET | Nexcella, Inc.
Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites...
NEXCELLA-Inverted-Color-2000x1500_nosubtitle_gray - rectangle.png
Nexcella Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
January 04, 2024 09:47 ET | Nexcella, Inc.
LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Vaishali Sanchorawala, MD, has joined the Nexcella Scientific...
NEXCELLA-Inverted-Color-2000x1500_nosubtitle_gray - rectangle.png
Nexcella Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
December 18, 2023 09:47 ET | Nexcella, Inc.
Dr. Radic led and authored landmark study demonstrating applicability of CAR-Ts in autoimmune diseases published in Science Translational Medicine, 2019 Dr. Radic is a recognized...
Picture1
Nexcella Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
December 11, 2023 09:46 ET | Nexcella, Inc.
100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6 lines of prior...
NEXCELLA-Inverted-Color-2000x1500_nosubtitle_gray - rectangle.png
Nexcella Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
November 21, 2023 09:56 ET | Nexcella, Inc.
NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance72 patients previously dosed with NXC-201 ex-U.S.First CAR-T program for...
NEXCELLA-Inverted-Color-2000x1500_nosubtitle_gray - rectangle.png
Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients
November 06, 2023 09:18 ET | Nexcella, Inc.
100% overall response rate observed in relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapyUpdated results will be communicated at the presentation time December 10,...
NEXCELLA-Inverted-Color-2000x1500_nosubtitle_gray - rectangle.png
Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients
November 06, 2023 08:46 ET | Nexcella, Inc.
95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy98% overall response rate observed in relapsed/refractory...
NEXCELLA-Inverted-Color-2000x1500_nosubtitle_gray - rectangle.png
Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board
October 26, 2023 09:03 ET | Nexcella, Inc.
Dr. Liedtke joins Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Stanford University Medical CenterDr. Liedtke is a recognized thought leader in...
NEXCELLA-Inverted-Color-2000x1500_nosubtitle_gray - rectangle.png
Nexcella Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
October 16, 2023 09:10 ET | Nexcella, Inc.
Successful completion supports expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S.NXC-201 is manufactured at our state-of-the-art cellular immunotherapy...